Compară metode
Examinează metodele selectate una lângă alta; rândurile care diferă sunt evidențiate.
| Criteriile West Haven pentru Encefalopatia Hepatică× | Indexul Cardinal al Simptomelor Gastroparezei× | |
|---|---|---|
| Domeniu | Gastroenterologie | Gastroenterologie |
| Familie | Process / pipeline | Process / pipeline |
| Anul apariției≠ | 1966 (original), 1978 (formalized) | 2003 |
| Autorul original≠ | West Haven Group (Parsons, Williams, Sherlock, Trey, Davidson) | Revicki, D. A., Rentz, A. M., Dubois, D., et al. |
| Tip≠ | Clinician-rated | Self-report |
| Sursa seminală≠ | Parsons, P. L., Williams, R., & Sherlock, S. (1978). The role of plasma amino acids in hepatic encephalopathy and the effect of branched-chain amino acid infusion. Gut, 19(10), 969–978. link ↗ | Revicki, D. A., Rentz, A. M., Dubois, D., Kahrilas, P., Stanghellini, V., Talley, N. J., & Tack, J. (2003). Development and validation of a patient-assessed gastroparesis symptom severity index. Alimentary Pharmacology & Therapeutics, 18(1), 141–150. link ↗ |
| Denumiri alternative≠ | Hepatic Encephalopathy Grading, HE Grade, West Haven Grade | GCSI |
| Înrudite | 4 | 4 |
| Rezumat≠ | The West Haven Criteria are the standard for grading hepatic encephalopathy (HE) severity, ranging from subclinical (Grade 0) to deep coma (Grade 4). Developed by Trey and Davidson in the 1960s and refined by the West Haven group, these criteria integrate mental status changes (confusion, asterixis, disorientation) and consciousness level to stage HE. The West Haven grade is a strong predictor of short-term prognosis in cirrhosis and guides urgency of intervention (lactulose, rifaxomicin, mannitol, intubation). | The Gastroparesis Cardinal Symptom Index (GCSI) is a validated, patient-reported outcome measure specifically designed to assess symptom severity in gastroparesis. Developed by Revicki and colleagues in 2003, the GCSI captures the three cardinal symptom clusters of gastroparesis: nausea and vomiting, postprandial fullness, and early satiety, plus bloating and stomach distension. The 9-item questionnaire is responsive to treatment changes and is increasingly used in clinical trials and practice to monitor gastroparesis progression and therapy response. |
| ScholarGateSet de date ↗ |
|
|